HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The Pregnancy in Polycystic Ovary Syndrome II (PPCOS II) trial: rationale and design of a double-blind randomized trial of clomiphene citrate and letrozole for the treatment of infertility in women with polycystic ovary syndrome.

Abstract
Polycystic Ovary Syndrome (PCOS) is a common cause of female infertility and first line treatment is currently oral clomiphene citrate, a selective estrogen receptor modulator, which results in both a high nonresponse rate and multiple pregnancy rate. Aromatase inhibitors such as letrozole may have more favorable ovarian and endometrial effects. The goal of the Pregnancy in Polycystic Ovary Syndrome II (PPCOSII) study is to determine the safety and efficacy of clomiphene citrate (CC) compared to letrozole, in achieving live birth in infertile women with PCOS. The population will consist of 750 infertile women with PCOS. Additionally, the couple will have no other major infertility factor. This will be a multi-center, prospective, double-blind clinical trial of CC vs. letrozole for 5 treatment cycles (or approximately up to 25 weeks). The randomization scheme will be coordinated through the central data coordinating center (DCC) and the randomization is stratified by each participating site. After progestin withdrawal as needed, 750 women will be equally randomized to two different treatment arms: A) CC 50mg every day for 5 days (days 3-7 of cycle), or B) letrozole 2.5mg every day for 5 days (days 3-7 of cycle), for a total of 5 cycles or 25 weeks. The dose will be increased in subsequent cycles in both treatment groups for non-response or poor ovulatory response up to a maximum of 150 mg of CC a day (×5 days) or 7.5mg of letrozole a day (×5 days). The primary analysis will use an intent-to-treat approach to examine differences in the live birth rate in the two treatment arms.
AuthorsRichard S Legro, Allen R Kunselman, Robert G Brzyski, Peter R Casson, Michael P Diamond, William D Schlaff, Gregory M Christman, Christos Coutifaris, Hugh S Taylor, Esther Eisenberg, Nanette Santoro, Heping Zhang, NICHD Reproductive Medicine Network
JournalContemporary clinical trials (Contemp Clin Trials) Vol. 33 Issue 3 Pg. 470-81 (May 2012) ISSN: 1559-2030 [Electronic] United States
PMID22265923 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, N.I.H., Extramural)
CopyrightCopyright © 2012 Elsevier Inc. All rights reserved.
Chemical References
  • Antineoplastic Agents
  • Fertility Agents, Female
  • Nitriles
  • Triazoles
  • Clomiphene
  • Letrozole
Topics
  • Adolescent
  • Adult
  • Antineoplastic Agents (therapeutic use)
  • Chi-Square Distribution
  • Clomiphene (therapeutic use)
  • Double-Blind Method
  • Female
  • Fertility Agents, Female (therapeutic use)
  • Health Status Indicators
  • Hirsutism (drug therapy)
  • Humans
  • Hyperandrogenism (drug therapy)
  • Infertility, Female (drug therapy, etiology)
  • Letrozole
  • Middle Aged
  • Nitriles (therapeutic use)
  • Ovulation Induction (methods)
  • Polycystic Ovary Syndrome (complications, drug therapy)
  • Pregnancy
  • Quality of Life (psychology)
  • Research Design
  • Triazoles (therapeutic use)
  • Women's Health
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: